Please login to the form below
Crohn's Disease
This page shows the latest Crohn's Disease news and features for those working in and with pharma, biotech and healthcare.
Homesick
susceptible are those with underlying co-morbidities like metabolic syndrome and cardiovascular disease. ... And then we have a whole ‘other’ group – patients with psoriasis, rheumatoid arthritis, Crohn’s disease, and also oncology patients.
Latest news
-
AbbVie says Allergan takeover delayed by FTC verdict
position. There’s no specified timeline for that review to complete, but AbbVie says it has “entered into a timing agreement with FTC staff that would likely result” in a ... AZ licensed the drug – which is in late-stage testing for ulcerative
-
After FDA refusal, Takeda builds case for subcutaneous Entyvio
Intravenous Entyvio is already available in 60 countries. Takeda has reported updated results from a trial of its subcutaneous formulation of Entyvio in Crohn’s disease, showing activity over a year ... An enhanced clinical response rate – defined as
-
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
according to AbbVie outperformed its rival across all the trial’s primary and secondary outcome measures. ... It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as
-
Takeda’s subcutaneous Entyvio formulation faces FDA rejection
treatments. It also indicated for use in adult patients with moderate-to-severe active Crohn’s Disease who have similarly had inadequate responses to standard treatments. ... after a lead-in period, were in remission from the inflammatory bowel disease
-
PMEA 2019: Recognising excellence in improving patient outcomes
Taking home this award was Takeda and Uptake Strategies for ENTYVIO’s Brand Healing (see image below), which positively impacted thousands of Ulcerative Colitis and Crohn’s Disease patients across the ... The two winners of this impressive award were
More from news
Approximately 20 fully matching, plus 152 partially matching documents found.
Latest Intelligence
-
Gut instincts lead Takeda to GI pipeline success
with Crohn’s disease or ulcerative colitis is expected to rise by around 25% by 2025, according to recent studies. ... This will help physicians take much better care of patients for something that is a lifetime disease.”.
-
Case study: 4 Sites – Navigating the course ahead
Client:SCITERION. Agency:N/A. Campaign:4 Sites: Navigating the course ahead. Timescale:N/A. Crohn’s disease – a chronic, debilitating and progressive disease – is on the increase worldwide, but remission
-
Drug launches to watch in 2019
The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other
-
Deal Watch October 2018
Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to
-
Innovation in merger control and the impact on the pharmaceutical sector
Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s
More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest appointments
-
TiGenix appoints Dr Marie Paule Richard
in phase III trials for complex perianal fistulas in Crohn's disease.
-
Ex J&J VP joins board of Immune
Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical
-
Former Novartis president joins Qu Biologics
His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
July 2020: diversity and inclusion in clinical trials round-up
Although there’s been an increase of inflammatory bowel disease (IBD) in underrepresented populations, there are still lots of misconceptions surrounding Crohn’s and ulcerative colitis among certain ethnic groups. ... Different ethnic groups are at
-
News: Living with Ulcerative Colitis and Crohn's Disease
Living with Ulcerative Colitis (UC) and Crohn’s Disease (CD) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.
-
Cello Health Insight wins EphMRA’s 2019 Market Research Excellence Award for 'Business Impact through Innovation'
Cello Health Insight in partnership with Janssen Pharmaceuticals has won EphMRA’s 2019 Market Research Excellence Award for 'Business Impact through Innovation'. ... The winning entry focused on exploring the Crohn’s Disease and Ulcerative Colitis
-
The Real & The Honestly Fake
If the audience’s attention span has decreased, agencies and advertisers must grab what little attention there is. ... about how to deal with Duchenne, the depictions of dragons to represent the struggles of suffering with Crohn’s disease, the
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease, ... in rare
More from PMHub
Approximately 4 fully matching, plus 10 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Trials resume for AZ/Oxford University COVID-19 vaccine
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Moderna inks R&D agreements with Vertex and Chiesi
- Building Stakeholder Relationships in the New Normal
- Personalized Digital Health Coaching
- Empowering Medtech Innovation
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
- Route 66: can remote working put two-thirds of us back on the road to engaged employment?
- Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
- Demonstrating the value of HCP self-serve portals
- Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....
Quick links
Infographics
